白蛋白结合型紫杉醇联合卡铂治疗晚期卵巢癌的疗效及不良反应分析

Analysis of the efficacy and adverse reaction of albumin paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer patients

目的探讨白蛋白结合型紫杉醇联合卡铂治疗晚期卵巢癌(AOC)患者的疗效及不良反应。方法选取2020年4月至2023年3月南平市第一医院收治的AOC患者,采用随机数字表法分为观察组和对照组。观察组给予白蛋白结合型紫杉醇联合卡铂治疗,对照组给予紫杉醇联合卡铂治疗。两组均连续治疗6个周期,记录两组患者的疗效,治疗前后肿瘤标志物、肿瘤血管生成因子、免疫相关因子及治疗期间的不良反应发生情况,并进行统计分析。结果共纳入122例患者,观察组61例,对照组61例。观察组治疗总有效率高于对照组(86.89%比65.57%),差异有统计学意义(P<0.05)。治疗6个周期后,观察组血清人附睾蛋白4、癌抗原125、癌抗原199、血管内皮生长因子、基质金属蛋白酶-9、基质细胞衍生因子1α、IL-10及IL-17水平均低于对照组,血清γ干扰素水平高于对照组,差异均有统计学意义(P<0.05);观察组不良反应总发生率低于对照组(32.79%比59.12%),差异有统计学意义(P<0.05)。结论应用白蛋白结合型紫杉醇联合卡铂治疗AOC效果较好,可以改善肿瘤标志物、肿瘤血管生成因子及免疫相关因子水平,且不良反应轻微。

Objective To discuss the efficacy and untoward reaction of albumin paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer(AOC)patients.Methods AOC patients admitted to Nanping First Hospital from Apr 2020 to Mar 2023 were selected and randomly divided into the observation group(treated with albumin paclitaxel com⁃bined with carboplatin)and the control group(treated with paclitaxel combined with carboplatin)using the random number table method.All the AOC patients were treated for 6 consecutive cycles.Researchers recorded the efficacy,tumor size,tu⁃mor markers,tumor angiogenesis factors,immune-related factors before and after treatment,and adverse reactions during treatment,and conducted statistical analysis.Results A total of 122 patients were included,61 cases in the observation group and 61 cases in the control group.The total effective rate of the observation group was higher than that of the control group(86.89%vs 65.57%),and the difference was statistically significant(P<0.05).After 6 cycles of treatment,the levels of se⁃rum HE4,CA125,CA199,VEGF,MMP-9,SDF-1α,IL-10,and IL-17 of the observation group were lower than those of the control group,and the levels of serum IFN-γwas lower than that of the control group,with significant differences(P<0.05).The total incidence of adverse reaction of the observation group was lower than that of the control group(32.79%vs 59.12%),the difference was statistically significant(P<0.05).Conclusion Albumin bound paclitaxel combined with carbopl⁃atin shows a good effect in the treatment of AOC,which can improve the levels of tumor markers,tumor angiogenesis factors,and immune-related factors with mild adverse reactions.